174 related articles for article (PubMed ID: 29434827)
1. Anti-inflammatory drug resistance selects putative cancer stem cells in a cellular model for genetically predisposed colon cancer.
Telang N
Oncol Lett; 2018 Jan; 15(1):642-648. PubMed ID: 29434827
[TBL] [Abstract][Full Text] [Related]
2. Stem cell models for genetically predisposed colon cancer.
Telang N
Oncol Lett; 2020 Nov; 20(5):138. PubMed ID: 32934706
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive agents inhibit aberrant proliferation of the aneuploid phenotype in a colon epithelial cell line established from Apc 1638N [+/-] mouse.
Katdare M; Kopelovich L; Telang N
Ann N Y Acad Sci; 2001 Dec; 952():169-74. PubMed ID: 11795437
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of Chemo-Resistant Stem Cells from a Mouse Model of Hereditary Non-Polyposis Colon Cancer.
Telang N
Stem Cells Cloning; 2021; 14():19-25. PubMed ID: 34234468
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.
Telang N; Katdare M
Oncol Rep; 2007 Apr; 17(4):909-14. PubMed ID: 17342335
[TBL] [Abstract][Full Text] [Related]
6. Cell culture model for colon cancer prevention and therapy: an alternative approach to animal experimentation.
Telang N; Katdare M
ALTEX; 2007; 24(1):16-21. PubMed ID: 17361317
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
8. Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome.
Telang N; Katdare M
Oncol Rep; 2009 Apr; 21(4):1017-21. PubMed ID: 19288003
[TBL] [Abstract][Full Text] [Related]
9. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
[TBL] [Abstract][Full Text] [Related]
10. Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice.
Yang K; Lamprecht SA; Shinozaki H; Fan K; Yang W; Newmark HL; Kopelovich L; Edelmann W; Jin B; Gravaghi C; Augenlicht L; Kucherlapati R; Lipkin M
J Nutr; 2008 Sep; 138(9):1658-63. PubMed ID: 18716166
[TBL] [Abstract][Full Text] [Related]
11. Drug-Resistant Stem Cells: Novel Approach for Colon Cancer Therapy.
Telang N
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269660
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
Hardiman KM; Liu J; Feng Y; Greenson JK; Fearon ER
PLoS One; 2014; 9(4):e96023. PubMed ID: 24763434
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer.
Telang N
Biomed Rep; 2017 Sep; 7(3):199-204. PubMed ID: 28819559
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
15. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
Foreman JE; Sorg JM; McGinnis KS; Rigas B; Williams JL; Clapper ML; Gonzalez FJ; Peters JM
Mol Carcinog; 2009 Oct; 48(10):942-52. PubMed ID: 19415698
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
17. Novel read through agent: ZKN-0013 demonstrates efficacy in APC
Graf MR; Apte S; Terzo E; Padhye S; Shi S; Cox MK; Clark RB; Modur V; Badarinarayana V
J Mol Med (Berl); 2023 Apr; 101(4):375-385. PubMed ID: 36808265
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.
Selmin OI; Fang C; Lyon AM; Doetschman TC; Thompson PA; Martinez JD; Smith JW; Lance PM; Romagnolo DF
J Nutr; 2016 Feb; 146(2):236-42. PubMed ID: 26609171
[TBL] [Abstract][Full Text] [Related]
19. A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression.
Zeineldin M; Cunningham J; McGuinness W; Alltizer P; Cowley B; Blanchat B; Xu W; Pinson D; Neufeld KL
Oncogene; 2012 May; 31(19):2423-37. PubMed ID: 21996741
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Specific Effects of Reduced β-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium.
Feng Y; Sakamoto N; Wu R; Liu JY; Wiese A; Green ME; Green M; Akyol A; Roy BC; Zhai Y; Cho KR; Fearon ER
PLoS Genet; 2015 Nov; 11(11):e1005638. PubMed ID: 26528816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
